Solana Q2 2025 Earnings Report

Solana EPS Results

• Actual EPS: -$79.73
• Consensus EPS: -$128.50
• Beat/Miss: Beat by +$48.77
• One Year Ago EPS: N/A

Solana Revenue Results

• Actual Revenue: $0.04 million
• Expected Revenue: $0.11 million
• Beat/Miss: Missed by -$70.00 thousand
• YoY Revenue Growth: N/A

Solana Announcement Details

• Quarter: Q2 2025
• Date: 8/14/2025
• Time: Before Market Opens
• Conference Call Date: Monday, August 18, 2025
• Conference Call Time: 4:00PM ET

Helius Medical Technologies, Inc. (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics. Frameworks of care vary by region but typically involve coordinated therapy protocols that combine the wearable stimulator, physical exercises and clinician-led monitoring. Helius supports its clinical users with training, device management and remote patient engagement tools to optimize rehabilitation outcomes.

Beyond its core PoNS offering, Helius is advancing an at-home digital therapy program that integrates software-guided exercises and telehealth support. The company collaborates with research institutions and rehabilitation centers to broaden the evidence base for its technology and explore applications in conditions such as mild traumatic brain injury, multiple sclerosis and stroke recovery. Ongoing clinical studies aim to expand indications and refine therapy protocols.

Founded in 2015 and headquartered in Toronto, Ontario, Helius Medical Technologies is led by President and Chief Executive Officer Dan M. Toutant. Since its inception, the company has pursued regulatory clearances across key markets and built partnerships with rehabilitation specialists to bring neuromodulation therapies to patients worldwide.